Scientific Advisory Board
About ExhaleNow’s Scientific Advisory Board
ExhaleNow is guided by a Scientific Advisory Board comprised of a panel of key opinion leaders and distinguished scientists.
The role of the members of the Scientific Advisory Board is to monitor and provide guidance on emerging allergen science, best practices, clinical studies and enhancements, and value-added technologies so we can continue to maintain the highest standards of scientific excellence that our customers and partners have come to expect from Inspirotec and its breakthrough product Exhale. Inspirotec is committed to bringing highly differentiated and high-value products to our core customers across Indoor Air Quality specialists, Allergists, Home Resale, and our direct to customer segments.
David has built and scaled multiple healthcare companies that resulted in the successful growth of his companies which leading to exits to strategic buyers. As a member of Inspirotec’s Scientific and Strategic Advisory Board, David’s extensive experiences and successful U.S. launch of new innovative products in the allergen & allergy testing and laboratory services will help drive Inspirotec’s Exhale patented air allergen devise, testing business, and consult services into its next growth phase.
Recent past successes include CEO: Armune BioScience (sold to Exact Sciences [EXAS] Dec.2017) and US President: Phadia US/AB which launched and grew ImmunocapTM blood allergen testing companyImmunoCAP® Specific IgE Blood Test (sold to Thermo Fisher Scientific [TMO] for $3.5 billion Sept. 2011).
Jonathan has 29 years of experience as a board certified and recertified allergist with over 285 publications related to areas of his expertise. A Professor of Clinical Medicine at the University of Cincinnati and a partner of Bernstein Allergy Group and Bernstein Clinical Research Center. His area of expertise is treatment of severe disease including asthma, difficult to treat chronic rhinitis, recurrent sinusitis with or without polyps, urticaria, angioedema including hereditary and acquired forms, atopic and contact dermatitis and other skin eruptions, food allergy including food challenges and oral immunotherapy, drug allergy including challenges and desensitizations, immunodeficiency (which may include neuropsychiatric disorders such as idiopathic autoimmune encephalopathy aka PANDAS/PANS), mast cell disorders with or without dysautonomia, eosinophilia disorders, environmental disorders including mold-related illnesses, women’s health issues including progesterone hypersensitivity, seminal plasma hypersensitivity and chronic vulvovaginal candida hypersensitivity, idiopathic anaphylaxis and other complex unexplained disorders. His practice is a referral center for patients around the country.
David Kelso is the distinguished Northwestern University Professor, Biomedical Engineering, McCormick School of Engineering and Applied Science; and a Director, Center for Innovation in Global Health Technologies (CIGHT). David has been a deep and extensive history in the fields of analytical instrumentation; medical devices, biosensors; kinetics of antibody and DNA binding reactions in solution and on solid phases. Before joining Northwestern, Professor Kelso developed a number of medical devices for the healthcare industry including Pandex founder, Chief Scientist at Baxter, and within intrapreneurial group Abbott Laboratories.
He was Chief Scientist at Baxter Healthcare’s Pandex Division from 1986 to 1992 and directed the team of engineers and scientists which developed the a high-throughput, multi-channel blood screening system which detected HIV, hepatitis and other infectious diseases. In 1981, Professor Kelso founded Pandex Laboratories and served as its president until 1986 when it was acquired by Baxter. The company developed, manufactured and sold analytical systems for biomedical research which included instruments and reagents for performing fluorescence immunoassays, cellular analysis and other research procedures.
Dr. Koziarz was President and CEO of Rubicon Genomics, a leader in the commercialization of preanalytical processes to improve the performance and capabilities of analytical platforms for research and clinical testing. The company was sold to Takara Bio in 2017. Previously he worked for 25 years in the Diagnostics Division of Abbott Laboratories, including 11 years as a corporate officer where he managed groups involved in product development, manufacturing and customer technical support, and new technology management. Since retirement from Abbott, he has been an active member of the entrepreneurial and venture communities, serving as an advisor to PhysIQ and several early stage, venture-backed life sciences companies. Prior to joining Abbott in 1979, Jim was a postdoctoral fellow in biochemistry at the University of Chicago. He earned a B.S. in chemistry from DePaul University, a PhD in biochemistry from the University of Chicago and won a National Research Service Award as a postdoctoral fellow.
Julian is a world renowned serial inventor who has made groundbreaking contributions to multiple fields of science. His group at Abbott Labs was responsible for developing lateral flow immunoassay technology, which led to the first home pregnancy tests. Prior to Abbott Labs, Julian’s group at Novartis (then CIBA-GEIGY) was responsible for inventing the Western Blot, an important method used today in molecular biology, biochemistry and immunogenetics for the characterization and detection of proteins. As a scientist, Julian is passionate about using evidence-based data to prevent human suffering.
A practicing allergist-immunologist for over 20 years, Dr. Detjen received his medical degree from Washington University School of Medicine in St. Louis and completed his residency and fellowship at Northwestern University Feinberg School of Medicine. Dr. Detjen is affiliated with multiple hospitals in the Chicagoland area, including NorthShore Evanston Hospital and Northwestern Memorial Hospital. He has helped thousands of families address allergies and asthma to live healthier, better lives. Dr. Detjen believes in Exhale – the product and the passionate team behind it. “I’m so thrilled that there’s finally a science-based solution for detecting allergens that trigger allergies and asthma,” Dr. Detjen says.